( NA sequence G10. Randomized: random as...)Cytos Biotechnology Reports Results from Phase IIa Study with,CYT003-QbG10 in Patients Suffering from Atopic Dermatitis,Health

NA sequence G10.
Randomized: random assignation of clinical trial participants to different treatment groups.
Th1 and Th2 type immune responses: describe T helper cell responses. T helper cells are a subset of T cells that
secrete a variety of mediators (cytokines) playing a role for other immune cells. A Th1 type immune response is
usually induced by viral or bacterial infection, or also by potent vaccination / immunotherapy. A Th2 type
immune response usually manifests an allergic reaction.

This foregoing press release may contain forward-looking statements that include words or phrases such as “will”, “considered to”,
“designed at”, “aimed to”, “determined to”, “intend” or other similar expressions. These forward-looking statements are subject to a
variety of significant uncertainties, including scientific, business, economic and financial factors, and therefore actual results may differ
significantly from those presented. There can be no assurance that any further therapeutic entities will enter clinical trials, that clinical
trial results will be predictive for future results, that therapeutic entities will be the subject of filings for regulatory approval, that any
drug candidates will receive marketing approval from the U.S. Food and Drug Administration or equivalent regulatory authorities, or that
drugs will be marketed successfully. Against the background of these uncertainties readers should not rely on forward-looking statements.
The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This
document does not constitute an offer or invitation to subscribe or purchase any securities of Cytos Biotechnology AG.
'"/>




Page: 1 2 3 4 5
Related medicine technology :

1. Cytos Reports Results from Phase I/IIa Study with CYT007-TNFQb for the Treatment of Psoriasis
2. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
3. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
4. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
5. Prana Biotechnology Presents New Key Findings on PBT2
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ASCO Annual Meeting
7. Generex Biotechnology Vaccine Strategy Presented at International Conference in London
8. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at AUA Annual Meeting
9. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
10. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
11. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis